Johnson & Johnson ($JNJ) and Smith & Nephew ($SNN) were reportedly close to combining their orthopaedics businesses in a transaction valued at roughly $34 billion. According to an October 23 Financial Times report, negotiations collapsed over who would lead the combined company, despite agreement on key financial terms. Under the reported proposal, J&J shareholders would have owned 50.1%… Read More »
Johnson & Johnson ($JNJ) is leaning toward spinning off DePuy Synthes, its orthopaedics business, rather than pursuing a sale. In prepared remarks accompanying its October 13 earnings release, CFO Joseph Wolk said a spinoff currently looks like the best way to create long-term shareholder value. J&J continues to evaluate other structures and expects the separation by mid-2027. A… Read More »
DePuy Synthes Spinoff Johnson & Johnson (JNJ) is slimming down again by getting back on the spinoff treadmill. The company announced last week that it plans to separate its orthopaedics division into a standalone company under the revived name DePuy Synthes, according to its press release. Unlike many spinoff announcements, the DePuy Synthes spinoff comes as a surprise,… Read More »
In American Psycho, Christian Bale’s character Patrick Bateman famously struggles to get a table at New York restaurant Dorsia. Hopefully brokers will be more accommodating to investors looking to get their hands on stock in Idorsia, which is to be spun out of Actelion (ALIOY) in the second quarter of 2017. Johnson & Johnson (JNJ) announced a deal… Read More »
Speculating about spinoffs – it’s not just for us, John Malone and deadline-driven journalists: 1) The Motley Fool handicaps the odds of a Johnson & Johnson (JNJ) spinoff in 2017. The basic premise is that JNJ has multiple segments with diverging sales trends (at least recently) so why not set one free. After playing through a few scenarios, the author ultimately suggests… Read More »